Breast cancer recurrence risk lingers for years after treatment

Endocrine therapy may be justified beyond the standard timeframe

The risk of breast cancer recurrence remains considerable in women after completing the standard five years of endocrine therapy, a review has found.

Breast Cancer

Breast cancer recurrences occurred at a steady rate for 15 years after being disease free with endocrine therapy, according to the meta-analysis of 88 studies involving more than 60,000 women with low-grade oestrogen receptor-positive breast cancer.

The absolute risk of cancer recurring was dependent on the original tumour status and grade, increasing from 13% with no nodal involvement to 34% among women with